Patient demographics and baseline characteristics
| . | HD-DXM (n = 95) . | PDN (n = 97) . | P . |
|---|---|---|---|
| Median age, y (range) | 43 (18-73) | 44 (18-75) | .473 |
| Gender, n (%) | 64 (67.4) | 72 (74.2) | .342 |
| Median platelet count, ×109/L (range) | 7 (0-29) | 8 (0-36) | .292 |
| Median bleeding score*, score (range) | 4 (0-13) | 4 (0-12) | .836 |
| Antiplatelet autoantibodies, n (%) | |||
| Anti–GPIIb-IIIa positive only | 22 (23.2) | 19 (19.6) | .599 |
| Anti–GPIb-IX positive only | 12 (12.6) | 11 (11.3) | .827 |
| Double positive | 18 (18.9) | 20 (20.6) | .857 |
| Double negative | 43 (45.3) | 47 (48.5) | .667 |
| . | HD-DXM (n = 95) . | PDN (n = 97) . | P . |
|---|---|---|---|
| Median age, y (range) | 43 (18-73) | 44 (18-75) | .473 |
| Gender, n (%) | 64 (67.4) | 72 (74.2) | .342 |
| Median platelet count, ×109/L (range) | 7 (0-29) | 8 (0-36) | .292 |
| Median bleeding score*, score (range) | 4 (0-13) | 4 (0-12) | .836 |
| Antiplatelet autoantibodies, n (%) | |||
| Anti–GPIIb-IIIa positive only | 22 (23.2) | 19 (19.6) | .599 |
| Anti–GPIb-IX positive only | 12 (12.6) | 11 (11.3) | .827 |
| Double positive | 18 (18.9) | 20 (20.6) | .857 |
| Double negative | 43 (45.3) | 47 (48.5) | .667 |
Bleeding score was graded by an ITP-specific bleeding scale by Khellaf et al.10